Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

98 projects found matching your search criteria :

  1. Strategy to overcome the "ionic checkpoint" and improve the antitumor immunotherapy.

    Call: OPUS 29 , Panel: NZ7

    Principal investigator: dr Beata Pyrzyńska

    Warszawski Uniwersytet Medyczny

  2. Functional nanomaterials based on drug–lipid–ligands as targeted delivery systems for anticancer agents in lung adenocar...

    Call: PRELUDIUM 24 , Panel: NZ7

    Principal investigator: Piotr Paweł Szyk

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  3. Development of novel 1,3-selenazol-2-one derivatives incorporated into self-emulsifying drug delivery systems as a strat...

    Call: OPUS 29 , Panel: NZ7

    Principal investigator: dr hab. Robert Czarnomysy

    Uniwersytet Medyczny w Białymstoku

  4. Dual cell cycle blockade and immune checkpoint inhibition as a potential strategy of sequential anticancer therapy

    Call: PRELUDIUM 24 , Panel: NZ7

    Principal investigator: Alicja Stanisława Słota

    Uniwersytet Jagielloński

  5. Next-Generation Exosome Therapy: Engineering NK Cell-Derived Vesicles for Targeted Cancer Treatment

    Call: SONATINA 9 , Panel: NZ6

    Principal investigator: dr Daria Nawrocka

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

  6. Mind the gap! Plasmonic nanocavity for spectroscopic trapping of local molecularrearrangements in DNA upon epigenetic mo...

    Call: OPUS 28 , Panel: ST4

    Principal investigator: prof. Ewelina Wioletta Lipiec

    Uniwersytet Jagielloński

  7. Investigation of the mechanism of enhanced liposome delivery to tumors and its application for dual target immunotherapy

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Piotr Rygiel

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  8. Environmental modulation of CDK4/6 inhibitor efficacy: Impact of mycotoxin alternariol exposure on anti-cancer therapies

    Call: SONATA 20 , Panel: NZ5

    Principal investigator: dr Anna Dominika Walczak-Szeffer

    Uniwersytet Medyczny w Łodzi

  9. Where Inhibition is not Enough- Development of Innovative Compounds for Targeted Degradation of Extracellular and Membra...

    Call: OPUS 28 (LAP) , Panel: NZ5

    Principal investigator: dr Marcin Skoreński

    Politechnika Wrocławska

  10. Application of bioconjugation strategy to the synthesis of anticancer Trojan horses

    Call: OPUS 28 , Panel: ST5

    Principal investigator: dr hab. Michał Piotr Antoszczak

    Uniwersytet im. Adama Mickiewicza w Poznaniu

  11. FA-PROTACs - Design and Synthesis of Compounds Based on Folic Acid for Degradation of Enzyme Involved in Folate Metaboli...

    Call: SONATA 20 , Panel: NZ5

    Principal investigator: dr Mateusz Daśko

    Politechnika Gdańska

  12. Canonical and non-canonical roles of DDK in oncogenesis: a cornerstone for the development of novel, potent anticancer t...

    Call: SONATA BIS 14 , Panel: NZ3

    Principal investigator: dr Jan Marian Suski

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  13. Evaluation of the relationship between doxorubicin resistance, epithelial-mesenchymal plasticity, and effects of selecte...

    Call: PRELUDIUM 23 , Panel: NZ5

    Principal investigator: Dominika Kunachowicz

    Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Farmaceutyczny z Oddziałem Analiutyki Medycznej

  14. Development and characterization of novel multitargeted organometallic tubulin polymerization inhibitors for enhancing t...

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: dr hab. Damian Nestor Plażuk

    Uniwersytet Łódzki

  15. Potential pharmacological strategies aimed at alleviating cognitive dysfunctions accompanying oncological therapy while ...

    Call: OPUS 26 , Panel: NZ5

    Principal investigator: dr hab. Joanna Monika Wierońska

    Instytut Farmakologii PAN

  16. Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act...

    Call: OPUS 26 , Panel: NZ5

    Principal investigator: dr Tomasz Krzysztof Prajsnar

    Uniwersytet Jagielloński, Wydział Biologii

  17. Development of dual immuno-oligo- biosensors for monitoring and controlling of the metastatic colorectal cancer and inve...

    Call: OPUS 25 , Panel: ST4

    Principal investigator: dr hab. Magdalena Stobiecka

    Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, Instytut Biologii

  18. Anticancer potential of TMPyP4 porphyrin in breast cancer photodynamic therapy and evaluation of the treatment safety

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Błażej Rubiś

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  19. Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marika Anna Frańczak

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  20. Investigating the anti-cancerous effect of antioxidant extract from spent coffee grounds on the functioning of normal an...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Adrianna Maria Piasek

    Politechnika Warszawska, Wydział Chemiczny

  21. Myeloid cell subpopulations as a source of effector cells for anticancer therapies using CAR chimeric receptors

    Call: OPUS 25 , Panel: NZ6

    Principal investigator: dr hab. Angelika Muchowicz

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  22. Targeting undruggable proteins involved in tumorigenesis – developing and characterization of advanced nanoplatform for ...

    Call: OPUS 25 , Panel: NZ6

    Principal investigator: dr hab. Monika Bzowska

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Bitechnologii

  23. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  24. Gaining control on XBP1s signaling as a starting point for novel cancer therapies

    Call: OPUS 24 , Panel: NZ7

    Principal investigator: prof. Rafał Artur Bartoszewski

    Uniwersytet Wrocławski, Wydział Biotechnologii

  25. Molecular insights into hypoxic tumors – for development of targeted cancer therapeutics

    Call: POLONEZ BIS 3 , Panel: NZ5

    Principal investigator: dr Marco Deiana

    Politechnika Wrocławska

  26. Pancreatic cancer oxygenation as a prognostic marker during anticancer therapy

    Call: OPUS 23 , Panel: NZ5

    Principal investigator: dr Martyna Krzykawska-Serda

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  27. Bioresorbable, electrospun nonwoven as a multi-drug delivery system for a combination glioblastoma therapy

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Monika Anna Musiał-Kulik

    Centrum Materiałów Polimerowych i Węglowych PAN

  28. Structure-guided design of histone demethylase inhibitors for cancer therapy.

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Piotr Henryk Małecki

    Instytut Chemii Bioorganicznej PAN

  29. Investigation of the MLK4 biology in breast cancer and search for new therapeutic strategies using innovative PROTAC com...

    Call: SONATA BIS 11 , Panel: NZ5

    Principal investigator: dr Anna Agnieszka Marusiak

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  30. Improvement of therapeutic safety of parenteral nutrition in cancer patients - the interplay between supportive drugs an...

    Call: PRELUDIUM 20 , Panel: NZ5

    Principal investigator: Szymon Tomczak

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  31. Exploring new roles for ADAR1 in cancer; generation of novel neoantigens, links with p53 and the effects of cancer treat...

    Call: WEAVE-UNISONO , Panel: NZ2

    Principal investigator: dr Małgorzata Kurkowiak

    Uniwersytet Gdański, Międzynarodowe Centrum Badań nad Szczepionkami Przeciwnowotworowymi

  32. Reversible senescence as a new mechanism of cancer cell resistance for chemotherapy. Analysis of the mechanism of cancer...

    Call: SONATINA 5 , Panel: NZ3

    Principal investigator: dr Karolina Anna Staniak

    Politechnika Warszawska, Wydział Chemiczny

  33. Single cell multi-omics in defining how specific oncogenic alterations shape the immune microenvironment and responses t...

    Call: OPUS 20 , Panel: NZ4

    Principal investigator: prof. Bożena Kamińska-Kaczmarek

    Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

  34. Delivery of immuno-activators to phagocytic cells in order to obtain an anti-tumor response

    Call: OPUS 20 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Piotr Rygiel

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  35. Polymersomes specifically releasing cGAMP and doxorubicin in tumor hypoxic regions as a new anti-cancer therapeutic stra...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr hab. Ryszard Smolarczyk

    Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

  36. Increasing the precision of chimeric antigen receptor (CAR)-mediated anticancer immunotherapy by using the chemokine-ind...

    Call: OPUS 19 , Panel: NZ6

    Principal investigator: dr hab. Radosław Zagożdżon

    Warszawski Uniwersytet Medyczny

  37. Photodynamic therapy combined with PD-1/PD-L1 blockade immunotherapy: new possibilities for the treatment of immunogenic...

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: dr hab. Janusz Marcin Dąbrowski

    Uniwersytet Jagielloński, Wydział Chemii

  38. DNA polymerase θ as a novel therapeutic target in personalized anticancer therapy

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Śliwiński

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  39. Foldback triplex-forming oligonucleotides as novel tools for G-quadruplex unfolding and selective inhibition of c-Myc on...

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: prof. Anna Pasternak

    Instytut Chemii Bioorganicznej PAN

  40. Investigation on PD-L1 biology for precise shaping of anticancer adoptive therapies

    Call: SONATA 15 , Panel: NZ6

    Principal investigator: dr Agnieszka Graczyk-Jarzynka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  41. Modulation of exosome production to support anti-cancer treatment

    Call: OPUS 18 , Panel: NZ7

    Principal investigator: dr Liliana Monika Czernek

    Centrum Badań Molekularnych i Makromolekularnych PAN

  42. Novel bispecific G-quadruplex conjugates as potential anticancer agents

    Call: PRELUDIUM 18 , Panel: NZ7

    Principal investigator: dr Carolina Sofia Pereira Roxo

    Instytut Chemii Bioorganicznej PAN

  43. Dual-targeted biodegradable polymeric micelles for anticancer drug delivery

    Call: SONATA BIS 9 , Panel: NZ7

    Principal investigator: dr Katarzyna Jelonek

    Centrum Materiałów Polimerowych i Węglowych PAN

  44. The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality

    Call: SONATA BIS 9 , Panel: NZ7

    Principal investigator: dr hab. Aneta Katarzyna Rogalska

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  45. Evaluation of endoplasmic reticulum stress control by endogenous lipids in the context of its anticancer therapeutic pot...

    Call: OPUS 17 , Panel: NZ5

    Principal investigator: dr Dariusz Maciej Pytel

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  46. Epigenetic effect on therapeutic activities of all-trans-retinoic acid in acute myeloid leukemia

    Call: OPUS 17 , Panel: NZ5

    Principal investigator: prof. Arthur Zygmunt Zelent

    Instytut Genetyki i Hodowli Zwierząt PAN

  47. DEVELOPMENT OF NEW CLASS PHOTOACTIVATED ANTICANCER-ANTIFUNGAL COMPOUNDS: CONJUGATES OF GOLD NANOPARTICLE-SUPPORTED QUINO...

    Call: OPUS 17 , Panel: NZ7

    Principal investigator: dr hab. Oleh M. Demchuk

    Katolicki Uniwersytet Lubelski Jana Pawła II, Wydział Medyczny

  48. Molekularny mechanizm nowej strategii indukcji apoptozy w eksperymentalnej celowanej terapii przeciwnowotworowej

    Call: ETIUDA 7 , Panel: NZ3

    Principal investigator: Damian Paweł Klóska

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  49. Cellular mechanisms and effects in vivo of selective lactate dehydrogenase A inhibitors in experimental models of mesoth...

    Call: OPUS 16 , Panel: NZ7

    Principal investigator: prof. Godefridus J Peters

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  50. STING protein activation combined with anti-vascular agent as a novel strategy for anticancer therapy

    Call: OPUS 16 , Panel: NZ5

    Principal investigator: dr hab. Ryszard Smolarczyk

    Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy